Literature DB >> 17921655

Immunotherapy for fungal infections with special emphasis on central nervous system infections.

Iyer G Parameswaran1, Brahm H Segal.   

Abstract

Opportunistic fungal infections are major causes of morbidity and mortality in the immunocompromized. Fungi have evolved complex and coordinated mechanisms to survive in the environment and the mammalian host. Fungi must adapt to "stressors" in the host, including nutrient scarcity, pH and reactive oxygen and nitrogen intermediates, in addition to evading host immunity. Knowledge of the immunopathogenesis of fungal infections has paved the way to promising strategies for immunotherapy. These include strategies that increase phagocyte number, activate innate host defense pathways in phagocytes and dendritic cells and stimulate antigen-specific immunity (e.g, vaccines). Immunotherapy must be tailored to specific immunocompromized states. Our review focuses on cryptococcosis and coccidioidomycosis because of the propensity of these diseases to involve the central nervous system (CNS). The CNS has long been considered "immunologically privileged" in the sense of being isolated from normal immune surveillance. This notion is only partially accurate. Immune-based therapies for fungal CNS disease are at an exploratory level and merit further evaluation in clinical trials.

Entities:  

Mesh:

Year:  2007        PMID: 17921655     DOI: 10.4103/0028-3886.35687

Source DB:  PubMed          Journal:  Neurol India        ISSN: 0028-3886            Impact factor:   2.117


  3 in total

1.  Liposomal resiquimod for the treatment of Leishmania donovani infection.

Authors:  Kevin J Peine; Gaurav Gupta; Deanna J Brackman; Tracey L Papenfuss; Kristy M Ainslie; Abhay R Satoskar; Eric M Bachelder
Journal:  J Antimicrob Chemother       Date:  2013-08-16       Impact factor: 5.790

2.  Central nervous system cryptococcosis in solid organ transplant recipients: clinical relevance of abnormal neuroimaging findings.

Authors:  Nina Singh; Olivier Lortholary; Françoise Dromer; Barbara D Alexander; Krishan L Gupta; George T John; Ramon del Busto; Goran B Klintmalm; Jyoti Somani; G Marshall Lyon; Kenneth Pursell; Valentina Stosor; Patricia Munoz; Ajit P Limaye; Andre C Kalil; Timothy L Pruett; Julia Garcia-Diaz; Atul Humar; Sally Houston; Andrew A House; Dannah Wray; Susan Orloff; Lorraine A Dowdy; Robert A Fisher; Joseph Heitman; Marilyn M Wagener; Shahid Husain
Journal:  Transplantation       Date:  2008-09-15       Impact factor: 4.939

3.  Host-mediated Leishmania donovani treatment using AR-12 encapsulated in acetalated dextran microparticles.

Authors:  M A Collier; K J Peine; S Gautam; S Oghumu; S Varikuti; H Borteh; T L Papenfuss; A R Sataoskar; E M Bachelder; K M Ainslie
Journal:  Int J Pharm       Date:  2016-01-05       Impact factor: 5.875

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.